David B. Schwartz is a Partner in the firm’s Antitrust and Competition Practice Group. As a former Lead Investigative Attorney at the U.S. Federal Trade Commission (FTC), David has significant experience in addressing the most complex antitrust and competition legal challenges.

David has made significant contributions to the field of antitrust law and litigation. He previously led high-profile FTC investigations from document discovery through investigational hearings and Commission processes— notably in the landmark case FTC et al. v. Amazon, where he led the FTC's investigation that resulted in filing the largest antitrust lawsuit in the FTC's history. During this time David worked daily with the FTC's top political and staff leadership.

David also has significant experience in the healthcare sector, having worked extensively on enforcement issues related to pharmaceutical pricing, e-provider consolidation, private equity provider acquisitions and Medicare Modernization Act patent settlements. He served in the FTC’s Healthcare Division of the Bureau of Competition from 2015-2022, and again in 2024. During his tenure, David led teams in important FTC wins in the Actavis reverse settlement payment litigation and the Surescripts exclusionary conduct case. David also has considerable experience with the agency's interest in private equity consolidation, both during his time as an Attorney Advisor for Commissioner Rohit Chopra and when arguing on behalf of the FTC in FTC v. US Anesthesia Partners.

Prior to joining the FTC, David was an associate at Quinn Emanuel. He was also a law clerk to the Honorable Sandra Segal Ikuta of the United States Court of Appeals for the Ninth Circuit.

David is widely recognized in the fields of healthcare, technology, and FTC enforcement. He has published articles in Bloomberg and Law360, has appeared on the ABA Antitrust Section’s Our Curious Amalgam Podcast, and has been quoted in The New York Times, Reuters, and the Guardian.